PDCD1 and neoplasm: Reactivation can result at least partly from increased antigen presentation by APCs, upregulation of HLA-I on tumor cells, and alleviating T-cells’ inhibition after treatments such as radiotherapy, EGFR TKIs, and anti-PD-1 immunotherapy [33].